NICE prices a year of healthy life so the NHS can ration

The UK NHS is a single payer with a fixed budget, so it literally cannot afford every medicine that works. The naive response is the hidden ration that most systems use: no explicit rule, and access decided piecemeal by whoever argues hardest.

NICE, created in 1999, picked the opposite route. It measures a treatment's benefit on a common scale — the quality-adjusted life year — then divides cost by benefit to get an incremental cost-effectiveness ratio. Drugs priced under £20,000–£30,000 per QALY gained are funded; expensive ones must cut their price.

One consistent number does the heavy work. It puts rationing in public, forces manufacturers to negotiate on price rather than on spin, and gives clinicians a defensible reason a drug was not approved.

The threshold rarely moved for twenty years; in 2026 the UK raised it to £25,000–£35,000 per QALY, expected to bring three to five more drugs into funding each year.

Put a price on a healthy year and ration by it

A QALY translates survival and pain into one number so different diseases can compete fairly.

A published threshold makes a rationing decision auditable instead of political.

Because price is endogenous to appraisal, the rule bends manufacturers toward lower prices.

The same decision rule across all drugs gives consistent, predictable outcomes.

Rationing is unavoidable; it can be hidden or done by rule. Publishing what a QALY is worth turns a back-room decision into a public standard and nudges makers to price below the line.

NICE's threshold became the model copied by assessment agencies in dozens of countries. It stayed at £20,000–£30,000 for two decades, drew criticism that it under-values innovation, and in April 2026 was raised to £25,000–£35,000 per QALY as part of a UK–US pharma trade agreement.